Article

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma

2019-05-20

Abstract excerpt

Chimeric antigen receptor engineered T cells (CAR T cells) have shown remarkable success in treating hematologic cancers. However, this efficacy has yet to translate to treatment in solid tumors. Pancreatic ductal adenocarcinoma (PDA) is a fatal malignancy with poor prognosis. Treatment options are limited and commonly associated with severe side effects. We have developed and characterized a second generation CAR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 470f2f4c-b8bf-5fa2-9c4e-2d2b67af0bc2
DOI: 10.1101/642934

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal AdenocarcinomaDOI 10.1101/642934Read

B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDACSemantic proximity Read

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read

Immunotherapy Combined with Chemotherapy versus Chemotherapy Alone in Advanced Pancreatic Ductal Adenocarcinoma: a Real-world Retrospective Cohort StudySemantic proximity Read

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read

Transcriptome-based identification of tumor-reactive and bystander CD8 + T cell receptor clonotypes in human pancreatic cancerSemantic proximity Read

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?Semantic proximity Read

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapySemantic proximity Read

Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccinesSemantic proximity Read

Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and MetastasisSemantic proximity Read

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read